Pharmacokinetic Interaction Between AZD3480 and Donepezil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00713765
Recruitment Status : Terminated (Ended prematurely - The trial never commenced.)
First Posted : July 11, 2008
Last Update Posted : August 15, 2014
Information provided by (Responsible Party):

Brief Summary:
The aims of this study are to 1) examine the effects of AZD3480 and donepezil on the blood concentrations of each other and 2) assess the safety and tolerability of the combined administration of AZD3480 with donepezil.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: AZD3480 Drug: Donepezil Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Double-blind, Randomised, Cross-over, Placebo-controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6
Study Start Date : December 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Arm Intervention/treatment
Experimental: A
AZD3480 + Donepezil
Drug: AZD3480
18 total doses of 40 mg, on days 1-18

Drug: Donepezil
One single dose of mg on day 5

Primary Outcome Measures :
  1. PK variables [ Time Frame: Frequent sampling occasions during ]

Secondary Outcome Measures :
  1. Safety variables (adverse events, blood pressure, pulse, safety lab) [ Time Frame: During the whole treatment period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of informed consent prior to any study-specific procedures
  • BMI between 18 and 30 kg/m2
  • Medical and surgical history and physical examination without any clinically significant findings
  • Genotyped as an EM, defined in this study as having ≥ 1.5 functional CYP2D6 alleles, or a PM, defined as having zero functional CYP2D6 alleles

Exclusion Criteria:

  • History of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator
  • Clinically significant illness as judged by the Investigator, within two weeks before the first administration of investigational product
  • Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00713765

United Kingdom
Research Site
Manchester, United Kingdom
Sponsors and Collaborators
Study Director: Hans Göran Hårdemark AstraZeneca R&D, Sodertalje, Sweden
Principal Investigator: Simon Constable ICON Development Solutions, Manchester, UK

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00713765     History of Changes
Other Study ID Numbers: D3690C00005
EudraCt No.2008-002847-17
First Posted: July 11, 2008    Key Record Dates
Last Update Posted: August 15, 2014
Last Verified: August 2014

Keywords provided by AstraZeneca:
Healthy volunteers

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents